Bio-rad Laboratories, Inc. · NYSE:BIO
Bio-rad Laboratories — J.P. Morgan Healthcare Conference 2023
26 slides from Bio-rad Laboratories's conference presentation, Jan 10, 2023
Slide 1: J.P. Morgan Healthcare Conference
2023 J.P. Morgan Healthcare Conference JANUARY 10,
Slide 2: Forward-Looking Statements & Use of Non-GAAP Reporting
Forward-Looking Statements & Use of Non-GAAP Reporting Forward-looking Statements. ‘Some statement inthis presentation may be forward-looking statements within the meaning of the Pete Secures Ligation Reform Ac of 1985, inching, without imitation, statements regarding management’ goals, plans and ex
Slide 3: Bio-Rad Today
3 Bio-Rad Today Global leader of innovative products in life science research and clinical diagnostics 70 $2.9B 8200 Years Strong Annual Sales* Employees Worldwide Performance ¥ Continuous Innovation A History of Contribution VY KeyCompetencies Fueling Ongoing Growth < Complementary Business Segment
Slide 4: Two Highly Complementary Business Segments
Two Highly Complementary Business Segments Vertically integrated, global commercial platform Life Science $1.37B*
Slide 5: Diversified Customer Base & Geographic Profile
Diversified Customer Base & Geographic Profile 70% recurring revenue provides stability and predictability across the business Diversified Customer Base Biopharma Hospital Labs Clinical Life Diagnostics Science Academic/ Govt. Transfusion Labs Worldwide Presence Asia-Pacific Americas Europe, Middle
Slide 6: Opportunities Across All Product Areas
Opportunities Across All Product Areas 80%+ of sales from products in which Bio-Rad has a leading market position Life Science Clinical Diagnostics Y Gene Expression Y Quality Controls Protein Quantitation Immunohematology Bioseparation Infectious Diseases v v Y Diabetes Monitoring v v v Y Molecular
Slide 7: Life Science Group Overview
Life Science Group Overview Established leadership positions with diversified presence and product mix Customer Segments Academic & Biopharma Government ‘Source: Bio-Rad Interna; 2021 Data Revenue Geography Europe, Middle East, & Africa Americas Asia-Pacific Consumables Products Instruments,
Slide 8: Life Science Strategy & Growth Pillars
Life Science Strategy & Growth Pillars Innovations fueling growth in translational research and biopharma Droplet Digital PCR Biopharma Production Cell Biology Broadening adoption Leveraging our advantages Building on a portfolio with new platforms for new therapeutic modalities of differentiated as
Slide 9: Droplet Digital PCR Growth Strategy
Droplet Digital PCR Growth Strategy Portfolio innovations driving broader adoption QX ONE Automation & Throughput Launched 2020 Qx600 Sensitivity & Multiplexing Launched 2022 Biopharma production and industrial-scale applied settings Setting a new standard in multiplex rare event detection QX Contin
Slide 10: Biopharma Production Growth Strategy
10 GROWTH PILLAR #2 Biopharma Production Growth Strategy Boosting productivity for purification of complex molecules * R&D investment focus on innovation — higher yields, fewer purification steps * Fuel demand through applications development * Offer breadth of products for varying scale and custome
Slide 11: Cell Biology Growth Strategy
GROWTH PILLAR #3 Cell Biology Growth Strategy Innovations positioned to gain share in attractive markets Single Cell Analysis $0.88) Rare Cell Detection $1.68) Drug Discovery & Antibody Screening —— $1.28) Flow Cytometry Assays $0.68) 11 Sources: Markets & Markets (var); DeciBio: Grandview Research;
Slide 12: Clinical Diagnostics Group Overview
2 Clinical Diagnostics Group Overview Global channel with strong recurring revenue Customer Segments Hospital Transfusion Laboratories Laboratories Reference Laboratories ‘Source: Bio-Rad Internal; 2021 Data Revenue Geography Europe, Middle Asia-Pacific East & Africa Americas Products
Slide 13: Clinical Diagnostics Strategy & Growth Pillars
Clinical Diagnostics Strategy & Growth Pillars Extending core franchises and enter molecular diagnostics Core Diagnostics Quality Controls & Informatics Molecular Diagnostics Expand installed base Extend utility of lab QC software Leverage RT-PCR and digital PCR globally and cross-sell menu and driv
Slide 14: Core Diagnostics Growth Strategy Highlights
4 GROWTH PILLAR #1 Core Diagnostics Growth Strategy Highlights: Clinical Immunology specialty testing is a growing global need BioPlex 2200 Immunoassay Platform * Differentiated platform for complex disease diagnostics serving growing Autoimmune and Infectious Disease testing * Expanding global inst
Slide 15: Quality Controls Growth Strategy Highlights
GROWTH PILLAR #2 Quality Controls Growth Strategy Highlights: A complete offering for laboratory quality control Unity QC Data Management Software * Largest QC data set for peer reporting, 65+ million data points per month, which enables lab quality and productivity * Daily software usage drives pro
Slide 16: Molecular Diagnostics Growth Strategy Highlights
GROWTH PILLAR #3 Molecular Diagnostics Growth Strategy Highlights: A two-pronged approach Syndromic infectious disease molecular diagnostics * Enter high-growth Acute Care Syndromic testing market; $2B+ growing at 8%+ / * Leverages Bio-Rad CFX PCR instrument installed base; Expand to new clinical la
Slide 17: Advancing Our Continued Transformation — A Three Phased Approach
7 Advancing Our Continued Transformation — A Three Phased Approach Improving financial performance 3 Accelerated ad a Growth Performance . = Mix & market segment focus & Operational = Operating margin expansion Improvement + Channel performance + Increase innovation 1 2020 - 2023 + Leverage operatio
Slide 18: Enhancing Our Financial Profile Through 2025
18 Enhancing Our Financial Profile Through 2025 ¢ Accelerating our revenue growth profile 0 9% Target Core Revenue CAGR Currency Neutral ¢ Further improving our cost structure ° Expanding profitability * Creating shareholder value through prudent 28% capital deployment Target Profitability Adjusted
Slide 19: 2022 in Review
19 2022 in Review Return to normalcy YY Supply chain issues showing signs of alleviating Y Continued strong product demand Y Strengthened operational foundation Addressing inflation Y Good core growth
Slide 20: Environmental & Social Responsibility Goals
Environmental & Social Responsibility Goals Progress on all fronts 2017 + Goals for 2030 SSS SSS 46% carbon emission reduction EE) TD 100% renewable electricity 45% women in U.S. leadership roles 60% of U.S. workforce from under-represented groups 25% reduction of non-recyclable packaging
Slide 21: Key Takeaways
ai Key Takeaways Accelerating our revenue growth profile Further improving our cost structure Expanding profitability Targeted M&A to enhance growth Creating shareholder value through disciplined capital deployment i
Slide 22: Thank you
Thank you
Slide 23: Appendix
Slide 24: Reconciliation of GAAP to Non-GAAP Financial Measures
24 Reconciliation of GAAP to Non-GAAP Financial Measures GAAP net sales Legal settlements Non-GAAP net sales GAAP cost of goods sold ‘Amortization of purchased intangibles Legal settlements Acquisition related benefits (costs) (1) Legal matters Restructuring benefits (costs) Other non-recurring item
Slide 25: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures Year Ended Year Ended Year Ended Year Ended Year Ended December 31, %of December31, sof ~—=December 31, ‘boot December 31, %ot December 31, %ot 2017 revenue 2018 revenue 2019 revenue 2020 revenue 2021 revenue GAAP net sales $ 2,160,153 $ 2,280,41
Slide 26: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures Year Ended Year Ended Year Ended Year Ended Year Ended December 31, of December 31, ot December 31, ot December 31, ‘hot December 31, of 2017 revenue 2018 revenue 2019 revenue, 2020 revenue 2024 revenue. GAAP net sales $ 2,160,153 $2,280,415 $ 2,
Bio-Rad Laboratories — J.P. Morgan Healthcare Conference 2023 on 6ix